GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Endocyte Inc (NAS:ECYT) » Definitions » Pretax Margin %

Endocyte (Endocyte) Pretax Margin % : -14,660.47% (As of Sep. 2018)


View and export this data going back to 2011. Start your Free Trial

What is Endocyte Pretax Margin %?

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Endocyte's Pre-Tax Income for the three months ended in Sep. 2018 was $-12.61 Mil. Endocyte's Revenue for the three months ended in Sep. 2018 was $0.09 Mil. Therefore, Endocyte's pretax margin for the quarter that ended in Sep. 2018 was -14,660.47%.

The historical rank and industry rank for Endocyte's Pretax Margin % or its related term are showing as below:


ECYT's Pretax Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -172.84
* Ranked among companies with meaningful Pretax Margin % only.

Endocyte Pretax Margin % Historical Data

The historical data trend for Endocyte's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Endocyte Pretax Margin % Chart

Endocyte Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
Pretax Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -27.80 7.76 -58,957.14 -62,697.14 -78,662.86

Endocyte Quarterly Data
Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -70,506.06 -65,876.92 -53,768.75 -82,607.14 -14,660.47

Competitive Comparison of Endocyte's Pretax Margin %

For the Biotechnology subindustry, Endocyte's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Endocyte's Pretax Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Endocyte's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Endocyte's Pretax Margin % falls into.



Endocyte Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Endocyte's Pretax Margin for the fiscal year that ended in Dec. 2017 is calculated as

Pretax Margin=Pre-Tax Income (A: Dec. 2017 )/Revenue (A: Dec. 2017 )
=-55.064/0.07
=-78,662.86 %

Endocyte's Pretax Margin for the quarter that ended in Sep. 2018 is calculated as

Pretax Margin=Pre-Tax Income (Q: Sep. 2018 )/Revenue (Q: Sep. 2018 )
=-12.608/0.086
=-14,660.47 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Endocyte  (NAS:ECYT) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


Endocyte Pretax Margin % Related Terms

Thank you for viewing the detailed overview of Endocyte's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Endocyte (Endocyte) Business Description

Traded in Other Exchanges
N/A
Address
Endocyte Inc is a biopharmaceutical company developing targeted therapies for the treatment of cancer and inflammatory diseases using precision medicine. Precision medicine is a medical discipline seeking to treat diseased cells with minimal impact on healthy cells. The company uses its proprietary technology to create novel small-molecule drug conjugates and companion imaging agents. The company's therapeutic areas are non-small cell lung, breast, colorectal, kidney, endometrial, prostate, and ovarian cancers; solid tumors; polycystic kidney disease; and inflammation.
Executives
Patrick Machado director 201 SPEAR STREET, 3RD FLOOR, SAN FRANCISCO CA 94107
John C Aplin director ONE AMERICAN SQUARE STE 2850, INDIANAPOLIS IN 46282
David R. Mcavoy officer: General Counsel C/O ENDOCYTE, INC., 3000 KENT AVENUE, SUITE A1-100, WEST LAFAYETTE IN 47906
Alison A. Armour officer: Chief Medical Officer C/O ENDOCYTE, INC., 3000 KENT AVENUE, SUITE A1-100, WEST LAFAYETTE IN 47906
Dawn Svoronos director C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Marc D Kozin director
Michael T. Andriole officer: Chief Financial Officer C/O ENDOCYTE, INC., 3000 KENT AVENUE, SUITE A1-100, WEST LAFAYETTE IN 47906
Lesley Russell director 41 MOORES RD., FRAZER PA 19355
Beth Taylor officer: VP Finance & Chief Acctg Off 3000 KENT AVENUE, SUITE A1-100, WEST LAFAYETTE IN 47906
Michael A. Sherman director, officer: President and CEO 3000 KENT AVE STE A1-100, WEST LAFAYETTE IN 47906
Fred A Middleton director 400 SOUTH EL CAMINO REAL STE 1200, SAN MATEO CA 94402-1708
Peter D Meldrum director 320 WAKARA WAY, SALT LAKE CITY UT 84108
Ann Hanham director ONE EMBRACADERO CTR, STE 2700, SAN FRANCISCO CA 94111
Chandra D Lovejoy officer: VP of Regulatory Affairs C/O PRONAI THERAPEUTICS, INC. 2150 - 885 WEST GEORGIA ST VANCOUVER A1 V6C 3E8
David D. Meek officer: Chief Commercial Officer 3000 KENT AVENUE; SUITE A1-100, WEST LAFAYETTE IN 47906